Linerixibat
Brand names: Lynavoy · Active ingredient: Linerixibat
In short: LYNAVOY is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients. Limitations of Use Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g.
What is Linerixibat used for?
LYNAVOY is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.
Limitations of Use
Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy) .
Linerixibat dosage
The recommended dosage of LYNAVOY is 40 mg orally twice daily. Swallow tablets whole at least 30 minutes before any food or beverage (other than water) .
If a dose is missed, take the missed dose as soon as possible and at least 30 minutes before your next meal, then resume the original dosing schedule. If a dose is missed by more than 6 hours, skip the dose and resume the original dosing schedule. Do not take a double dose to make up for a missed dose.
Administer LYNAVOY at least 4 hours before or 4 hours after taking a bile acid binding resin .
How to take Linerixibat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Administration Instructions
Instruct patients to take LYNAVOY at least 30 minutes before any food or beverage (other than water) .
Instruct patients that if they miss a dose of LYNAVOY to take it as soon as possible and at least 30 minutes before their next meal, then resume the original dosing schedule. If a dose is missed by more than 6 hours, skip the dose and resume the original dosing schedule. Advise patients to not take a double dose to make up for a missed dose .
Instruct patients to take LYNAVOY at least 4 hours before or 4 hours after taking a bile acid binding resin .
Liver Test Abnormalities
Advise patients that their healthcare provider will obtain liver tests before starting LYNAVOY and periodically during treatment with LYNAVOY .
Diarrhea
Advise patients to monitor for dehydration. Consider interrupting or discontinuing LYNAVOY treatment if diarrhea persists. .
Fat-Soluble Vitamin (FSV) Deficiency
Advise patients that INR (for vitamin K) and serum levels of vitamins A, D, E will be obtained before starting treatment and periodically during treatment to assess for FSV deficiency . …
Warnings & precautions
Do not take this medicine if: None.
In Study 1, liver test elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients . Obtain baseline liver tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TB], direct bilirubin [DB], alkaline phosphatase [ALP]) prior to initiating treatment with LYNAVOY and monitor the levels per standard clinical practice for PBC patients during treatment with LYNAVOY. If new liver test elevations occur, monitor ALT, AST, TB, DB, and ALP more frequently. If liver test elevations persist, discontinue LYNAVOY.
Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY .
If diarrhea occurs, advise patients to monitor for dehydration. Consider interrupting or discontinuing LYNAVOY treatment if diarrhea persists.
LYNAVOY may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamins A, D, E, and K .
Obtain serum FSV levels (vitamins A, D, and E) and INR prior to initiation of LYNAVOY and monitor the levels periodically during treatment, along with any clinical manifestations of FSV deficiency. Supplement with FSV if FSV deficiency is diagnosed. Consider discontinuing LYNAVOY if FSV deficiency persists or worsens despite adequate FSV supplementation.
Bleeding
Bleeding was observed more frequently in LYNAVOY-treated patients compared to placebo-treated patients . If bleeding occurs, interrupt LYNAVOY treatment and evaluate for potential FSV deficiency. LYNAVOY can be restarted if FSV deficiency is corrected, levels are maintained, and bleeding has resolved.
Bone Fracture
IBAT inhibitors have been associated with bone fractures. Monitor bone health and ensure adequate FSV levels.
Linerixibat side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Liver Test Elevations
Diarrhea
Fat-Soluble Vitamin Deficiency
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LYNAVOY is based on Study 1, a randomized, double-blind, placebo-controlled, 24-week study of LYNAVOY 40 mg administered orally twice daily .
Drug discontinuation due to adverse reactions was seen more frequently in LYNAVOY-treated patients (14%) than in placebo-treated patients (5%). Diarrhea, abdominal pain, ALT increase, and AST increase were the most common causes of treatment discontinuation.
Common Adverse Reactions
Table 1 displays the most common adverse reactions that occurred in at least 5% of LYNAVOY-treated patients in Study 1.
Adverse Reaction | LYNAVOY (n = 119) n (%) | Placebo (n = 118) n (%)
DiarrheaDiarrhea includes diarrhea and frequent bowel movements. | 74 (62) | 21 (18)
Abdominal painAbdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort. …
Drug interactions
Instruct patients to take LYNAVOY at least 4 hours before or 4 hours after taking a bile acid binding resin . Based on in vitro data, bile acid resins may bind linerixibat in the gut . Concomitant use of bile acid binding resins with LYNAVOY can potentially inhibit the effects of LYNAVOY on the ileal bile acid transporter (IBAT).
About this medicine
Linerixibat is an orally administered IBAT inhibitor. Linerixibat has the chemical name 3-((((3R,5R)-3-butyl-3-ethyl-7-methyloxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepin-8-yl)methyl)amino)pentanedioic acid. The molecular formula of linerixibat is C28H38N2O7S with a molecular weight of 546.68 g/mol. Linerixibat has the following chemical structure:
"*" represent chiral centers.
Linerixibat is a white to off-white solid. Its solubility in aqueous solutions is pH-dependent and varies from very slightly to slightly soluble. LYNAVOY is available for oral administration as tablets containing 40 mg linerixibat and the following excipients: croscarmellose sodium, magnesium stearate and microcrystalline cellulose.
The tablet film-coating contains black iron oxide, hypromellose, polyethylene glycol, red iron oxide, and titanium dioxide.
How it works: Linerixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids in the terminal ileum leading to their increased fecal elimination. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c00317c8-709c-4707-a6d1-632bff123026. Read the full official label on DailyMed.